0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover0.01%IV-146.91%PremiumJan 17, 2025Expiry Date5.95Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-1.0000Delta0.0000Gamma0.68Leverage Ratio0.0000Theta0.0000Rho-0.68Eff Leverage0.0000Vega
Nevro Stock Discussion
6 mins ago
Nevro's Hfx Iq™ Spinal Cord Stimulation With AI Technology Receives Ce Mark Certification in Europe, Increasing Product Expansion Globally
Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
Nevro Corp. (NYSE: NVRO) has announced the FDA approval and market release of HFX iQ™ with HFX AdaptivAI™, an AI-driven spinal cord stimulation (SCS) system for chronic pain management. This technology leverages insights from over 100,000 patients and more than 100 million data points to provide personalized, responsive pain relief in real time.
Key features of HFX Adaptiv...
News:
• $PyroGenesis Canada (PYR.US)$ +5.9% (announces that the negotiation for the land-based system to destroy PFAS contract has been suspended and discontinued)
• $Immatics (IMTX.US)$ +3.1% (announces a clinical data update for the IMA203)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +1.6% (rising with softness in futures)
• $Nevro (NVRO.US)$ +1.4% (comments on $UnitedHealth (UNH.US)$ medical coverage policy u...
No comment yet